AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Type-1 angiotensin II receptor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P30556

UPID:

AGTR1_HUMAN

Alternative names:

AT1AR; AT1BR; Angiotensin II type-1 receptor

Alternative UPACC:

P30556; Q13725; Q8TBK4

Background:

The Type-1 angiotensin II receptor (AT1AR), also known as AT1BR, plays a pivotal role in regulating blood pressure and sodium retention by the kidney. This receptor, upon binding with angiotensin II, activates G-alpha proteins and phospholipase C, leading to increased cytosolic Ca(2+) concentrations and stimulation of protein kinase C. Additionally, AT1AR is implicated in the internalization of the SARS-CoV-2 virus through a complex with ACE2 and the viral spike protein, mediated by dynamin 2-dependent endocytosis.

Therapeutic significance:

Renal tubular dysgenesis, a severe disorder characterized by abnormal renal tubular development leading to perinatal death, is associated with mutations affecting AT1AR. Understanding the role of AT1AR could open doors to potential therapeutic strategies for this condition and other blood pressure-related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.